P harmaceuticals

We have represented some of the largest and specialty companies in the pharmaceutical sector, providing counsel on a variety of matters, including mergers and acquisitions, competition, regulatory, real estate, environmental and labor matters.

Below is a list (which is organized in alphabetical order based on our client’s name) of selected matters which, is intended to give a brief indication of our experience in the pharmaceutical sector:

  • Counsel to Valeant Pharmaceutical International in the pre-merger notification to the FCC regarding the merger with Biovail Corporation.
  • Counsel to Berry Plastics Inc., a global leader in healthcare packaging that develops a variety of products for the medical and healthcare industries, in the acquisition of the healthcare containers and closures business from Rexam PLC for US$140 million.
  • Counsel to Bristol Myers Squibb in the sale of its Clairol division to Procter & Gamble.
  • Counsel to Bristol Myers Squibb in connection with its collaboration agreement with Reckitt Benckiser Group PLC for a number of market-leading over- the-counter consumer health care brands in Mexico.
  • Counsel to Bristol Myers Squibb in the demolition and dismantling of one of their industrial facilities in San Angel Mexico City.
  • Counsel to Bristol Myers Squibb in the sale and lease-back of their office headquarters located in San Angel in Mexico City.
  • Counsel to Bristol Myers Squibb in connection with its industrial facility in Tlalpan, Mexico City, in conducting regular audits of the site’s compliance with Mexican environmental laws, as part of its global corporate environmental compliance program.
  • Counsel to Bristol Myers Squibb in their day-to-day legal-environmental matters regarding various areas of their operations in Mexico, including advice to perform internal environmental audits at its current facilities, in the assignment of water concession titles and post-operation matters at its former facilities.
  • Counsel to Bristol Myers Squibb in their labor collective matters in connection with their industrial facility in Tlalpan, Mexico City and their employment day to day advice.
  • Counsel to Colgate Palmolive on the sale to Genomma Laboratories in Mexico, a direct subsidiary of Genomma Lab Internacional, of the Wildroot brand/line of business and Alert and Nórdiko brands/lines of business.
  • Counsel to Endo Pharmaceutical Inc., in the acquisition of 100% Grupo Farmacéutico Somar, a privately owned pharmaceutical company based in Mexico.
  • Counsel to Endo Pharmaceutical Inc., in the negotiation of several transition services agreements, sanitary registration assignments and other ancillary documents which impacted the relationship of 1414 employees, in connection with the acquisition of the group of companies comprising Grupo Farmacéutico Somar.
  • Counsel to the controlling shareholders of Farmacias Ahumada, S.A., in the US$637 million sale to Grupo Casa Saba, S.A.B. de C.V., of Farmacias Ahumada, S.A. and Farmacias Benavides, S.A.B. de C.V., two of the largest drug-store chains in Chile, México and Peru.
  • Counsel to Forest Finance B.V. as lender in connection with a secured financing to Moksha8 Farmacéutica, S. de R.L. de C.V.
  • Counsel to General Atlantic LLC in its equity investment in Invekra, SA.P.I. de C.V., parent company of Laboratorios Sanfer.
  • Counsel to Gedeon Richter in its acquisition of a majority stake in its marketing partner DNA Pharmaceuticals to establish its direct presence in Mexico.
  • Counsel to Invekra, S.A.P.I. de C.V., owner of Laboratorios Sanfer, one of the largest independent pharmaceutical companies in Mexico, operating in nine countries across Latin America, in the acquisition of Grupo IDISA, a manufacturer of a variety of veterinary drugs and vaccines.
  • Counsel to Novartis AG in the sale to Eli Lilly and Company of its animal health care business, for approximately US$5.4 billion.
  • Counsel to Panasonic Healthcare in the acquisition of the diabetes care business of German pharmaceuticals company Bayer, for approximately US$1.1 billion dollars.